Founding Member Companies
Akili Interactive is a prescription digital medicine company combining the scientific rigor of a biotech with the ingenuity of the tech industry to reinvent medicine. The company is developing novel prescription medicine and assessments delivered not through a pill but through high-quality action video game experiences that have been designed to directly treat cognitive dysfunction associated with a range of medical conditions. Akili is advancing a late-stage pipeline of programs across neurology and psychiatry, including Attention Deficit/Hyperactivity Disorder ADHD, depression, Autism spectrum disorder and multiple sclerosis/inflammation. Akili’s lead candidate is in a Phase 3 randomized, controlled pivotal study in pediatric ADHD with topline results expected by the end of 2017. For more information, visit www.akiliinteractive.com.
Propeller empowers people with asthma and COPD to live measurably better lives. In 2010 Propeller set out to modernize respiratory medicine, enable people to minimize the impact of asthma and COPD on their daily lives, and connect them to their physicians, environment and community. Propeller’s information-powered approach to respiratory management guides physicians and patients to the optimal path of therapy for each individual. With connected inhalers, digital interfaces, and personalized insights, participants receive personal guidance and expert direction anytime. Propeller received the American Telemedicine Association’s 2016 President’s Award for Innovation in Remote Healthcare and was recognized as one of the top “Fierce 15” medical device companies in 2015 by FierceMedicalDevices. In 2017, Fast Company named Propeller as one of the most innovative companies in Health. For more information visit: www.propellerhealth.com
Voluntis creates digital companions that empower people to self-manage their treatment in remote collaboration with their health care teams. Dedicated to chronic conditions, Voluntis’ products aim to personalize treatment, support team-care coordination and improve real-world outcomes. Voluntis leverages its expertise in digitizing clinical algorithms and its Theraxium technology platform to design its companion solutions. These include Insulia and Diabeo in diabetes (with Sanofi), eCO in ovarian cancer (with AstraZeneca) and Zemy in breast cancer (with Roche). For more information, visit http://www.voluntis.com/.
WellDoc® is the leading digital health company revolutionizing chronic disease management to help transform lives. We are the first digital health company based on a life science business model, and our foundation is built on randomized clinical trials that demonstrate significant clinical outcomes. We have mastered diabetes management by taking an aggressive and innovative approach that utilizes sophisticated logic and precise algorithms, and integrates the most advanced mobile technology, behavioral insight, and diabetes education for those living with type 2 diabetes. Our FDA-cleared, proven digital therapeutic, BlueStar®, provides real-time and timely individualized coaching and support, as well as diabetes educational tools that are actionable and personal. For more information, visit www.welldoc.com.
DTA Board of Directors
Chief Strategy Officer, WellDoc
Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®, the first FDA-cleared mobile prescription therapy for adults with type 2 diabetes. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. In 2013, Anand was named “Maryland Healthcare Innovator of the Year” in the field of mobile health.
Anand was the founder and immediate-past president of the In-Building Wireless Alliance, and teaches advanced wireless courses to senior officers in the US Department of Defense at the Institute for Defense and Business. Prior to joining PRTM, Anand was a member of the scientific staff at Bell Northern Research and Nortel Networks. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University. He also holds a BS in electrical and computer engineering from Carleton University.
Chief Executive Officer, Voluntis
Pierre is the founder and CEO of Voluntis, a digital therapeutics company focused on medication therapy optimization. Based on the Theraxium platform, Voluntis digital companions empower people to self-manage their treatment in remote collaboration with their healthcare teams, notably in diabetes and oncology. Pierre has 19 years of experience in the digital health sector in Europe and the US. He previously worked at GE Medical Systems and Healthcenter Internet Services. He is the coordinator of eHealth France Alliance, which represents companies active in the digital health space in France. Pierre holds an MS in Computer Science from Ecole Centrale Paris.
Eddie Martucci, PhD
Chief Executive Officer, Akili Interactive
Eddie is a co-founder of Akili Interactive Labs, a digital medicine company creating treatments and assessments for cognitive disorders that are delivered through immersive, high quality video game mechanics. As part of PureTech Health, Eddie previously co-founded two other health-focused start-ups, and helped launch their digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City, MO, focused on healthcare entrepreneurship. Prior to that, he completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry, focusing on structure-based drug design. Eddie received his B.S. in Biochemistry from Providence College, and his M.Phil. and Ph.D. from Yale University.
Eddie frequently serves on discussion panels for industry and academic events related to healthcare innovation, has appeared in media including CNN’s Vital Signs with Sanjay Gupta, and Akili has received recognition including the 2014 Future of Health Technology product award, 2015 50-on-Fire Boston, and the #1 health company in Entrepreneur magazine’s 100 Brilliant Companies of 2016.
David Van Sickle
Chief Executive Officer, Propeller Health
David was formerly an Epidemic Intelligence Service Officer with the Centers for Disease Control and Prevention, and a Robert Wood Johnson Foundation Health and Society Scholar at the University of Wisconsin School of Medicine and Public Health. He writes about asthma epidemiology, medical anthropology, and global chronic respiratory disease at davidvansickle.com.
Chief Commercial Officer, Pear Therapeutics
Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations.
He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals.
Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.
CEO, Healthware International
Roberto is a pioneer in digital health and a recognized thought leader, people-inspiring founder, serial entrepreneur and global manager. Trained as a medical doctor and in marketing communications, his passion for medicine, computer science and human-technology interactions have led to his lifelong commitment and dedication to the advancement and spreading of digital healthcare, he holds a strong belief that digital innovations and technology will be the most impactful drivers of change in healthcare.
Roberto is currently CEO at Healthware International the largest, independent, healthcare consultancy (more than 700 people in Europe and USA through the Intouch Solutions joint venture) helping life sciences companies, healthcare stakeholders and start-ups navigate the transformation in healthcare, from strategy to technology.
Roberto is also very active in the digital health ecosystem in various advisor capacities both in Europe and in USA to companies, start-ups and investors; among others he has been recognized Best Industry Leader by The Health 2.0 – 10 Year Global Retrospective Awards in 2016, nominated Transformational Leader at The 2017 PM360 ELITE Awards and named among the 100 Most Inspiring People by PharmaVOICE in 2017. He is a regular keynoter at numerous conferences, has been President of the HealthTech Summit and is chairman at Frontiers Health, which emerged as one of the leading digital health conferences globally.
Marc is focused on scaling the digital health sector through his involvement in growth investment, M&A, and large industry partnerships. He has been advising on digital health strategy and investment through his company Digitalhealth.Network since early 2015, and has been active in digital health since 2010. Marc’s passionate about fostering the global digital health ecosystem, with a particular focus on bringing together investors and entrepreneurs as well as innovators from the Life Sciences industry, with the aim of driving scale and adoption of digital health solutions. Since 2015, Marc is advisor to Merck Global Health Innovation Fund, the largest dedicated global digital health venture fund. In addition, Marc acts as advisor on digital health strategy and partnerships to Nestle, works with Private Equity investors on digital health portfolio acquisitions, and helps selected growth stage companies connect with potential acquirers.
Marc is part of the Steering Committee for Frontiers Health, and has chaired the HealthTech Summit, having developed this in 2 years time into the leading European event for investors in digital health. Over the years he has built up a unique personal network of 1000+ digital health stakeholders, including leading PE/VC investors representing >$1400Bn, founders/CEO’s of digital health companies and Life Sciences industry innovators. For more than 6 years now, Marc’s monthly digital health newsletter is recognised as one of the most comprehensive sources of market information by many of the 1000+ readers. Marc regularly participates as speaker and jury member in pan-European events focused on digital health investment.
Marc has 20+ years of experience working with the Life Sciences and Technology industry, in health information (IQVIA/IMS Health), Life Sciences management consulting (Accenture), and biotech (Merck-Serono). Most recently, Marc was responsible for M&A and digital health partnerships at Oracle Health Sciences, where his involvement ranged from the acquisition of ClearTrial and partnership with Greenphire to Oracle’s investment in Proteus Digital Health.
Megan Coder, PharmD, MBA
Executive Director, Digital Therapeutics Alliance
Megan Coder, PharmD, MBA, is Executive Director of the Digital Therapeutics Alliance. DTA represents the healthcare industry’s leading manufacturers of clinically validated digital therapeutic solutions. DTA’s mission is to broaden the understanding, adoption, and integration of digital therapeutic solutions into mainstream healthcare through education, advocacy, and research.
With more than a decade of experience in the healthcare industry, Megan has held a variety of roles within the areas of strategic planning, partnership development, project management, and regulatory affairs. Prior to joining DTA, Megan worked with Voluntis, the Pharmaceutical Care Management Association, the National Association of Boards of Pharmacy, the Pharmacy Technician Certification Board, and Iodine.
A proud Badger, Megan graduated from the University of Wisconsin—Madison School of Pharmacy and completed an Executive Residency in Association Management & Leadership with the American Pharmacists Association Foundation.